Dechra Pharmaceuticals Given Hold Rating at N+1 Singer (DPH)
Dechra Pharmaceuticals (LON:DPH)‘s stock had its “hold” rating reiterated by investment analysts at N+1 Singer in a note issued to investors on Monday, StockRatingsNetwork.com reports. They currently have a GBX 740 ($12.20) price objective on the stock. N+1 Singer’s price target would indicate a potential upside of 1.37% from the company’s current price.
Shares of Dechra Pharmaceuticals (LON:DPH) opened at 725.00 on Monday. Dechra Pharmaceuticals has a 52 week low of GBX 604.00 and a 52 week high of GBX 791.50. The stock’s 50-day moving average is GBX 690.7 and its 200-day moving average is GBX 695.7. The company’s market cap is £631.9 million.
A number of other analysts have also recently weighed in on DPH. Analysts at FinnCap reiterated a “buy” rating on shares of Dechra Pharmaceuticals in a research note to investors on Monday. They now have a GBX 800 ($13.18) price target on the stock. Separately, analysts at Panmure Gordon reiterated a “buy” rating on shares of Dechra Pharmaceuticals in a research note to investors on Monday, January 6th. They now have a GBX 850 ($14.01) price target on the stock. Finally, analysts at Panmure Gordon reiterated a “buy” rating on shares of Dechra Pharmaceuticals in a research note to investors on Thursday, December 19th. They now have a GBX 850 ($14.01) price target on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Dechra Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of GBX 774.67 ($12.77).
Dechra Pharmaceuticals PLC (LON:DPH) is an international veterinary pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.